OWL Metabolomics’ Post

🏥Explore the next evolution in assessing liver health with OWLiver, an advanced, non-invasive assessment that utilizes metabolomic technology to evaluate liver function through the analysis of 39 distinct lipids.🧬 📊 Designed for precise detection across all harmful stages of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), OWLiver offers healthcare providers a dependable resource. It enables the monitoring of disease progression, ensuring meticulous attention to patient health 🩺. 🔍 This novel method marks a considerable advancement in the field of liver disease diagnosis, emphasizing patient ease while maintaining diagnostic precision. Lead the way in healthcare with OWLiver, merging the forefront of scientific innovation with clinical performance.

🏥Explore the next evolution in assessing liver health with OWLiver, an advanced, non-invasive assessment that utilizes metabolomic technology to evaluate liver function through the analysis of 39 distinct lipids.🧬 📊 Designed for precise detection across all harmful stages of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), OWLiver offers healthcare providers a dependable resource. It enables the monitoring of disease progression, ensuring meticulous attention to patient health 🩺. 🔍 This novel method marks a considerable advancement in the field of liver disease diagnosis, emphasizing patient ease while maintaining diagnostic precision. Lead the way in healthcare with OWLiver, merging the forefront of scientific innovation with clinical performance.

Discover the future of liver health assessment with OWLiver®️, a groundbreaking, non-invasive test that harnesses the power of metabolomic technology to analyze liver activity through 39 specific lipids. OWLiver®️ is designed to accurately diagnose patients across all harmful phases of Metabolic Dysfunction-Associated Fatty Liver Disease (MASLD), providing a reliable tool for healthcare professionals. With the capability to monitor patient progression or regression of MASLD and hepatic fibrosis, OWLiver®️ ensures vigilant patient care.  This innovative approach represents a significant leap forward in liver disease diagnostics, prioritizing patient comfort without compromising accuracy. Stay ahead in patient care with OWLiver®️ - where cutting-edge science meets clinical excellence. #LiverHealth #Metabolomics #MASLD

We are happy to share the latest publication from Ariel Precision Medicine following our mission to advance a deeper understanding of the impact of Recurrent Acute and Chronic Pancreatitis. https://lnkd.in/gQk4mBSw Traditional research studies have considered hospital admissions as the gold standard for measuring the attack rate and thus healthcare burden for Recurrent Acute and Chronic Pancreatitis. In hopes of better estimating the burden of disease, we reached out to patients to fill out a brief questionnaire focused on pancreatic events that are managed "outside" of a hospital or ER setting. We discovered that patients suffer through multiple events per year that are managed outside of the hospital setting, highlighting that true event rate may be significantly underrepresented in the literature. Gaining a better understanding of the impact of pancreatic disease and event rate is foundational to developing targeted therapeutics and more effective treatments aimed at improving patient lives and health outcomes. Congratulations to Phil Greer, Jessica Gibson, Tory Moore, CFA and David C Whitcomb MD PhD #healthoutcomes #precisionmedicine #datascience #pancreatitis

Cardiogenic shock (CS) is characterized by low cardiac output and sustained tissue hypoperfusion that may result in end-organ dysfunction and death. CS is associated with high short-term mortality, and its management remains challenging despite recent advances in therapeutic options. Timely diagnosis and multidisciplinary team-based management have demonstrated favourable effects on outcomes. We aimed to review evidence-based practices for managing patients with ischemic and non-ischemic CS, detailing the multi-organ supports needed in this critically ill patient population.

Prevalence, Predictors, Echocardiographic Features, and Clinical Outcomes of Infective Endocarditis in Patients with Streptococcus agalactiae Septicemia https://t.co/BKTir5lEPv #EurekaMag

Check out our work on point-of-care liver health diagnostics at the University of Edinburgh, and please participate in the surveys. #innovation #healthcare #medtech #invitrodiagnostics #pointofcaretesting #ICUReExplore #InnovateUK #UoE

Ventricular septal defects are a rare complication after acute myocardial infarction with a mortality close to 100% if left untreated. However, even surgical or interventional closure is associated with a very high mortality and currently no randomized controlled trials are available addressing the optimal treatment strategy of this disease. This state-of-the-art review and clinical consensus statement will outline the diagnosis, hemodynamic consequences and treatment strategies of ventricular septal defects complicating acute myocardial infarction with a focus on current available evidence and a focus on major research questions to fill the gap in evidence.

🧬 Discover at INASL 2024 from August 7-10 to explore our poster presentation titled "One-step non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis and fibrosis in high-risk population" using the OWLiver test. This innovative approach aims to improve the accuracy and ease of diagnosing these conditions, offering significant benefits for patient care and management. Our test demonstrates high sensitivity (86.1%) and positive predictive value (85.3%) for detecting MASH. The OWLiver Panel shows reliable accuracy in identifying MASH and significant fibrosis among high-risk individuals. This advancement in non-invasive diagnostics can revolutionize how we approach liver health and patient care.🔬 🗣️ Don't miss this opportunity to learn more about how our work can impact liver health and the future of medical diagnostics during the oral presentation of the poster on the Session - Special Interest Group (SIG) – MASLD the 9th August from 8:00 AM – 8.50 AM in Hall – 1. #INASL2024 #LiverHealth #Metabolomics #MedicalInnovation #Healthcare

Today on #WorldLiverDay, we acknowledge the vital role the liver plays in maintaining our health and well-being. As we focus on #LiverHealth, advancements in analytical technologies contribute significantly to our understanding and ability to diagnose liver-related conditions. At #Shimadzu, we're committed to advancing liver health research, and one of the tools utilised is Liquid Chromatograph Mass Spectrometry #LCMSMS. This cutting-edge technology allows us to precisely analyze #BileAcids, and crucial biomarkers for liver function assessment and disease diagnosis. 💡Explore how our 𝙇𝘾-𝙈𝙎/𝙈𝙎 𝙈𝙚𝙩𝙝𝙤𝙙 𝙋𝙖𝙘𝙠𝙖𝙜𝙚 𝙛𝙤𝙧 𝘽𝙞𝙡𝙚 𝘼𝙘𝙞𝙙𝙨 boosts liver health research and clinical diagnostics 🔗 https://lnkd.in/dJxM4nAG Together, let's continue to innovate and raise awareness about Liver Health to ensure healthier lives for all 🛡️